SMI

SMI hits 14,000+ points: Swiss resilience fuels a steady rally driven by oil‑price stability, geopolitical optimism and banking consolidation, pointing to sustained growth.

SMI shifts: Galderma & Sandoz join the blue‑chip lineup, boosting the index 0.63% on 21 Sept 2026 amid a European market rebound and €1.559bn cap.

SMI’s 2 Sep 2026 close at 14,334.8 shows a modest gain driven by Novartis pharma rally, defying higher oil prices and bond yields.

SMI’s July 2026 shake‑up: Swisscom, Kühne+Nagel and Sandoz exit, Galderma and Sandoz biosimilar enter—shifting the index toward high‑growth life‑sciences and tech. Learn why investors should watch the new composition now.

Swiss SMI June 2026: modest 0.04 % rise to 14,181.5 points, Roche gains boost optimism while Geberit falls, amid calm geopolitical tension and European recovery.

SMI gains momentum on 19 May 2026, closing above 13 300 points amid easing Middle‑East tensions and solid Swiss corporate earnings—why investors should keep a keen eye on this resilient Swiss benchmark.

SMI gains early April 2026: 12 728,48 points, 0.47 % rise on March 31, buoyed by Nestlé, Kühne + Nagel and rising oil prices.

SMI swings: a week of sharp dips, geopolitical tension, yet a new all‑time high—find out how Swiss investors are holding back and what this means for tomorrow’s markets.

SMI near 52‑week high, flat 0.02% in Jan 2026 – Swiss market consolidates amid European optimism and Asian momentum. Find out what drives next moves.

Swiss Market Index ends 2025 near‑flat at 13 240.59, reflecting cautious investor sentiment and steady €1.532 bn market cap.